Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about the safety and effectiveness of
giving KDS-1001 in combination with a standard stem cell transplant to patients with acute
myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML).
KDS-1001 is a study product created using certain immune cells called natural killer (NK)
cells collected from a third-party donor.